Click Holdings Limited (NASDAQ:CLIK) Short Interest Up 913.9% in July

Posted by Stanley Muller on Aug 13th, 2026

Click Holdings Limited (NASDAQ:CLIK – Get Free Report) was the target of a large growth in short interest during the month of July. As of July 31st, there was short interest totaling 19,660 shares, a growth of 913.9% from the July 15th total of 1,939 shares. Approximately 1.7% of the company’s stock are short sold. Based on an average daily trading volume, of 577,994 shares, the days-to-cover ratio is presently 0.0 days.

Analyst Upgrades and Downgrades

CLIK has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Click in a research report on Wednesday, June 24th. Wall Street Zen upgraded shares of Click to a “hold” rating in a report on Saturday, June 13th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Read Our Latest Report on Click

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Click stock. Renaissance Technologies LLC bought a new stake in shares of Click Holdings Limited (NASDAQ:CLIK – Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned about 1.23% of Click at the end of the most recent reporting period.

Click Stock Performance

NASDAQ CLIK traded down $0.01 on Thursday, hitting $1.40. The stock had a trading volume of 6,842 shares, compared to its average volume of 1,342,035. Click has a 52-week low of $1.32 and a 52-week high of $14.40. The firm has a 50-day moving average of $1.51 and a 200-day moving average of $2.35.

Click (NASDAQ:CLIK – Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.10 earnings per share (EPS) for the quarter. The business had revenue of $3.79 million for the quarter.

About Click

(Get Free Report)

Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.